Exelixis Inc
XETRA:EX9

Watchlist Manager
Exelixis Inc Logo
Exelixis Inc
XETRA:EX9
Watchlist
Price: 21.09 EUR Market Closed
Market Cap: 6.8B EUR
Section:
Wall Street Price Targets
Wall Street Price Targets
Revenue Forecast
Operating Income Forecast
Net Income Forecast
See Also
Price Target
Average
+51%
Revenue
Forecast
+5%
Operating Income
Forecast
+7%
Net Income
Forecast
+1%

Wall Street
Price Targets

EX9 Price Targets Summary
Exelixis Inc

Wall Street analysts forecast EX9 stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for EX9 is 21.81 EUR with a low forecast of 16.5 EUR and a high forecast of 26.62 EUR.

EX9 Lowest Forecast
Wall Street Target
16.5 EUR
22% Downside
EX9 Average Forecast
Wall Street Target
21.81 EUR
3% Upside
EX9 Highest Forecast
Wall Street Target
26.62 EUR
26% Upside
Lowest
Price Target
16.5 EUR
22% Downside
Average
Price Target
21.81 EUR
3% Upside
Highest
Price Target
26.62 EUR
26% Upside
Exelixis Inc Competitors:
Price Targets
B
BCAX
Bicara Therapeutics Inc
134% Upside
CPRX
Catalyst Pharmaceuticals Inc
48% Upside
1167
Jacobio Pharmaceuticals Group Co Ltd
47% Downside
NBIX
Neurocrine Biosciences Inc
48% Upside
B
BCAX
Bicara Therapeutics Inc
134% Upside
CPRX
Catalyst Pharmaceuticals Inc
48% Upside
1167
Jacobio Pharmaceuticals Group Co Ltd
47% Downside
NBIX
Neurocrine Biosciences Inc
48% Upside
VYGR
Voyager Therapeutics Inc
301% Upside
RCKT
Rocket Pharmaceuticals Inc
459% Upside
ELDN
Eledon Pharmaceuticals Inc
227% Upside
300685
Amoy Diagnostics Co Ltd
40% Upside

Revenue
Forecast

Revenue Estimate
Exelixis Inc

For the last 8 years the compound annual growth rate for Exelixis Inc's revenue is 35%. The projected CAGR for the next 3 years is 10%.

35%
Past Growth
10%
Estimated Growth
Estimates Accuracy
-1%
Average Miss
What are analyst estimates?

Operating Income
Forecast

Operating Income Estimate
Exelixis Inc

The compound annual growth rate of Exelixis Inc's operating income for the next 3 years is 18%.

N/A
Past Growth
18%
Estimated Growth
Estimates Accuracy
-2%
Average Miss
What are analyst estimates?

Net Income
Forecast

Net Income Estimate
Exelixis Inc

The compound annual growth rate of Exelixis Inc's net income for the next 3 years is 21%.

N/A
Past Growth
21%
Estimated Growth
Estimates Accuracy
21%
Average Beat
What are analyst estimates?

See Also

Summary
EX9 intrinsic value, competitors valuation, and company profile.
DCF Valuation
EX9 stock valuation using Discount Cash Flow valuation method.
Relative Valuation
EX9 stock valuation using valuation multiples.
Wall Street Estimates
EX9 price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
EX9 stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
Why do you have more estimates than other sites?

Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.

What is EX9's stock price target?
Price Target
21.81 EUR

According to Wall Street analysts, the average 1-year price target for EX9 is 21.81 EUR with a low forecast of 16.5 EUR and a high forecast of 26.62 EUR.

What is Exelixis Inc's Revenue forecast?
Projected CAGR
10%

For the last 8 years the compound annual growth rate for Exelixis Inc's revenue is 35%. The projected CAGR for the next 3 years is 10%.

What is Exelixis Inc's Operating Income forecast?
Projected CAGR
18%

The compound annual growth rate of Exelixis Inc's operating income for the next 3 years is 18%.

What is Exelixis Inc's Net Income forecast?
Projected CAGR
21%

The compound annual growth rate of Exelixis Inc's net income for the next 3 years is 21%.

Back to Top
ALPHA SPREAD
Follow us
Join more than 248,900+ value investors using Alpha Spread
Create a free account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks Wide Economic Moat Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2025 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.